Long-term sertraline treatment increases expression and decreases phosphorylation of glycogen synthase kinase-3B in platelets of patients with late-life major depression

Journal of Psychiatric Research

Volumn 46, Issue 8, 2012, Pages 1053-1058

  Joaquim, Helena P G ^a   Talib, Leda L ^a   Forlenza, Orestes V ^a   Diniz, Breno S ^a,b   Gattaz, Wagner F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antidepressant treatment; Biomarkers; Glycogen synthase kinase 3 beta; Platelets

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3; SERINE; SERTRALINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT COURSE THERAPY; THROMBOCYTE FUNCTION; TREATMENT DURATION; UPREGULATION;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIDEPRESSIVE AGENTS; BLOOD PLATELETS; DEPRESSIVE DISORDER, MAJOR; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOENZYME TECHNIQUES; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PHOSPHORYLATION; RESIDENCE CHARACTERISTICS; SERTRALINE;

EID: 84863438743     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.04.020     Document Type: Article

References (38)

1. American Psychiatric Association Diagnostic and statistical manual of mental disorders 2000, American Psychiatric Association, Washington, DC. (4th ed., text revision).
2. Balaraman Y., Limaye E.R., Levey A.I., Srinivasan S. Glycogen synthase kinase 3B and Alzheimer's disease: pathophysiological and therapeutic significance. Cellular and Molecular Life Science 2006, 63:1226-1235.
3. Beaulieu J.M., Zhang X., Rodriguiz R.M., Sotnikova T.D., Cools M.J., Wetsel W.C., et al. Role of GSK3 beta in behavioral abnormalities induced by serotonin deficiency. Proceedings of National Academy of Sciences 2008, 105:1333-1338.
4. Beaulieu J.M. Not only lithium: regulation of glycogen synthase kinase-3 by antipsychotics and serotonergic drugs. International Journal of Neuropsychopharmacology 2007, 10:3-6.
5. Byers A.L., Yaffe K. Depression and risk of developing dementia. Nature Reviews Neurology 2011, 7(6):323-331. [Review].
6. Chin P.C., Majdzadeh N., D'Mello S.R. Inhibition of GSK3β is a common event in neuroprotection by different survival factors. Molecular Brain Research 2005, 137:193-201.
7. de Sousa R.T., van de Bilt M.T., Diniz B.S., Ladeira R.B., Portela L.V., Souza D.O., et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neuroscience Letters 2011 Apr 20, 494(1):54-56. Epub 2011 Mar 6.
8. Devanand D.P., Pelton G.H., Marston K., Camacho Y., Roose S.P., Stern Y., et al. Sertraline treatment of elderly patients with depression and cognitive impairment. International Journal of Geriatriac Psychiatry 2003, 18(2):123-130.
9. Diniz B.S., Teixeira A.L., Talib L.L., Mendonça V.A., Gattaz W.F., Forlenza O.V. Increased soluble TNF receptor 2 in antidepressant-free patients with late-life depression. Journal of Psychiatric Research 2010, 44(14):917-920.
10. Diniz B.S., Teixeira A.L., Talib L.L., Mendonça V.A., Gattaz W.F., Forlenza O.V. Serum brain-derived neurotrophic factor level is reduced in antidepressant-free patients with late-life depression. The World Journal of Biological Psychiatry 2010, 11(3):550-555.
11. Diniz B.S., Talib L.L., Joaquim H.P.G., De-Paula V.R.J., Gattaz W.F., Forlenza O.V. Platelet GSK3B activity in patients with late-life depression: marker of depressive episode severity and cognitive impairment?. The World Journal of Biological Psychiatry 2011, 12(3):216-222.
12. Dranovsky A., Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biological Psychiatry 2006 Jun 15, 59(12):1136-1143.
13. Embi N., Rylatt D.B., Cohen P. Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. European Journal of Biochemistry 1980, 107:519-527.
14. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I disorders 2002, Research Version, Patient Edition. (SCID-I/P), Biometrics Research, New York State Psychiatric Institute, New York.
15. Forlenza O.V., Almeida O.P., Stoppe A., Hirata E.S., Ferreira R.C.R. Antidepressant efficacy and safety of low-dose sertraline and standard-dose imipramine for the treatment of depression in older adults: results from a double-blind, randomized, controlled clinical trial. International Psychogeriatrics 2001, 13(1):75-84.
16. Forlenza O.V., Torres C.A., Talib L.L., de Paula V.J., Joaquim H.P., Diniz B.S., et al. Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease. Journal of Psychiatric Research 2011, 45(2):220-224.
17. Forlenza O.V., Diniz B.S., Radanovic M., Santos F.S., Talib L.L., Gattaz W.F. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial. British Journal of Psychiatry 2011, 198(5):351-356.
18. Gould T.D., Manji H.K. Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005, 30:1223-1237.
19. Grimes C.A., Jope R.S. The multifaceted roles of GSK3b in cellular signaling. Progress in Neurobiology 2001, 65:391-426.
20. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery & Psychiatry 1960, 23:56-62.
21. Jope R.S., Roh M.S. Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions. Current Drug Targets 2006, 7:1421-1434.
22. Jope R.S., Yuskaitis C.J., Beurel E. Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochemistry Research 2007, 32:577-595.
23. Kessing L.V., Søndergård L., Forman J.L., Andersen P.K. Antidepressants and dementia. Journal of Affective Disorder 2009, 117(1-2):24-29. Epub 2009 Jan 12.
24. Kessing L.V., Forman J.L., Andersen P.K. Do continued antidepressants protect against dementia in patients with severe depressive disorder?. International Clinical Psychopharmacology 2011, 26(6):316-322.
25. Klein P.S., Melton D.A. A molecular mechanism for the effect of lithium on development. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:8455-8459.
26. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. In vivo regulation of glycogen synthase kinase-3beta (GSK3-beta) by serotonergic activity in mouse brain. Neuropsychopharmacology 2004, 29:1426-1431.
27. Li X., Friedman A.B., Zhu W., Wang L., Boswell S., May R.S., et al. Lithium regulates glycogen synthase kinase-3beta in human peripheral blood mononuclear cells: implication in the treatment of bipolar disorder. Biological Psychiatry 2007, 61:216-222.
28. Li X., Rosborough K.M., Friedman A.B., Zhu W., Roth K.A. Regulation of mouse brain glycogen synthase kinase-3 by atypical antipsychotics. International Journal Neuropsychopharmacology 2007, 10:7-19.
29. Mendes C.T., Mury F.B., de Sá Moreira E., Alberto F.L., Forlenza O.V., Dias-Neto E., et al. Lithium reduces Gsk3b mRNA levels: implications for Alzheimer disease. European Archives of Psychiatry and Clinical Neuroscience 2009, 259(1):16-22.
30. Messa C., Colombo C., Moresco R.M., Gobbo C., Galli L., Lucignani G., et al. 5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology (Berlin) 2003; Apr, 167(1):72-78. Epub 2003 Mar 11.
31. Muyllaert D., Kremer A., Jaworski T., Borghgraef P., Devijver H., Croes S., et al. Glycogen synthase kinase-3b, or a link between amyloid and tau pathology?. Genes, Brain and Behavior 2008, 7:57-66.
32. Nelson R.L., Guo Z., Halagappa V.M., Pearson M., Gray A.J., Matsuoka Y., et al. Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice. Experimental Neurology 2007 May, 205(1):166-176. Epub 2007 Feb 13.
33. Nunes P.V., Forlenza O.V., Gattaz W.F. Lithium and risk for Alzheimer's disease in elderly patients with bipolar disorder. British Journal of Psychiatry 2007, 190:359-360.
34. Pandey G.N., Ren X., Rizavi H.S., Dwivedi Y. Glycogen synthase kinase-3beta in the platelets of patients with mood disorders: effect of treatment. Journal of Psychiatry Research 2010, 44:143-148.
35. Peineau S., Bradley C., Taghibiglou C., Doherty A., Bortolotto Z.A., Wang Y.T., et al. The role of gsk-3 in synaptic plasticity. British Journal Pharmacology 2008, 153(Suppl. 1):S428-S437.
36. Polter A., Beurel E., Yang S., Garner R., Song L., Miller C.A., et al. Deficiency in the inhibitory serine-phosphorylation of glycogen synthase kinase-3 increases sensitivity to mood disturbances. Neuropsychopharmacology 2010, 35:1761-1774.
37. Prickaerts J., Moechars D., Cryns K., Lenaerts I., van Craenendonck H., Goris I., et al. Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania. Journal of Neuroscience 2006, 26:9022-9029.
38. Wang Q.M., Fiol C.J., DePaoli-Roach A.A., Roach P.J. Glycogen synthase kinase-3 beta is a dual specificity kinase differentially regulated by tyrosine and serine/threonine phosphorylation. Journal of Biological Chemistry 1994, 269:14566-14574.